RXDX Annual CFO
-$123.25 M
-$59.75 M-94.09%
31 December 2022
Summary:
As of February 5, 2025, RXDX annual cash flow from operations is -$123.25 million, with the most recent change of -$59.75 million (-94.09%) on December 31, 2022. During the last 3 years, it has fallen by -$103.06 million (-510.26%).RXDX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RXDX Quarterly CFO
-$39.54 M
+$1.58 M+3.84%
31 March 2023
Summary:
As of February 5, 2025, RXDX quarterly cash flow from operations is -$39.54 million, with the most recent change of +$1.58 million (+3.84%) on March 31, 2023. Over the past year, it has dropped by -$10.16 million (-34.56%).RXDX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RXDX TTM CFO
-$133.41 M
-$10.16 M-8.24%
31 March 2023
Summary:
As of February 5, 2025, RXDX TTM cash flow from operations is -$133.41 million, with the most recent change of -$10.16 million (-8.24%) on March 31, 2023. Over the past year, it has dropped by -$59.51 million (-80.53%).RXDX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RXDX Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -94.1% | -34.6% | -80.5% |
| 3 y3 years | -510.3% | -651.9% | -2436.8% |
| 5 y5 years | -510.3% | -651.9% | -2436.8% |
RXDX Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | +510.3% | +771.0% | +2436.8% |
Prometheus Biosciences Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2023 | - | -$39.54 M(-3.8%) | -$133.41 M(+8.2%) |
| Dec 2022 | -$123.25 M(+94.1%) | -$41.12 M(+72.1%) | -$123.25 M(+18.2%) |
| Sept 2022 | - | -$23.90 M(-17.2%) | -$104.31 M(+7.1%) |
| June 2022 | - | -$28.85 M(-1.8%) | -$97.39 M(+31.8%) |
| Mar 2022 | - | -$29.39 M(+32.5%) | -$73.90 M(+16.4%) |
| Dec 2021 | -$63.51 M | -$22.18 M(+30.6%) | -$63.51 M(+36.1%) |
| Sept 2021 | - | -$16.98 M(+216.9%) | -$46.65 M(+36.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2021 | - | -$5.36 M(-71.8%) | -$34.21 M(-18.1%) |
| Mar 2021 | - | -$18.99 M(+257.2%) | -$41.75 M(+49.0%) |
| Dec 2020 | -$28.02 M(+38.7%) | -$5.32 M(+17.1%) | -$28.02 M(+23.4%) |
| Sept 2020 | - | -$4.54 M(-64.8%) | -$22.70 M(+25.0%) |
| June 2020 | - | -$12.90 M(+145.3%) | -$18.16 M(+245.3%) |
| Mar 2020 | - | -$5.26 M | -$5.26 M |
| Dec 2019 | -$20.20 M | - | - |
FAQ
- What is Prometheus Biosciences annual cash flow from operations?
- What is the all time high annual CFO for Prometheus Biosciences?
- What is Prometheus Biosciences annual CFO year-on-year change?
- What is Prometheus Biosciences quarterly cash flow from operations?
- What is the all time high quarterly CFO for Prometheus Biosciences?
- What is Prometheus Biosciences quarterly CFO year-on-year change?
- What is Prometheus Biosciences TTM cash flow from operations?
- What is the all time high TTM CFO for Prometheus Biosciences?
- What is Prometheus Biosciences TTM CFO year-on-year change?
What is Prometheus Biosciences annual cash flow from operations?
The current annual CFO of RXDX is -$123.25 M
What is the all time high annual CFO for Prometheus Biosciences?
Prometheus Biosciences all-time high annual cash flow from operations is -$20.20 M
What is Prometheus Biosciences annual CFO year-on-year change?
Over the past year, RXDX annual cash flow from operations has changed by -$59.75 M (-94.09%)
What is Prometheus Biosciences quarterly cash flow from operations?
The current quarterly CFO of RXDX is -$39.54 M
What is the all time high quarterly CFO for Prometheus Biosciences?
Prometheus Biosciences all-time high quarterly cash flow from operations is -$4.54 M
What is Prometheus Biosciences quarterly CFO year-on-year change?
Over the past year, RXDX quarterly cash flow from operations has changed by -$10.16 M (-34.56%)
What is Prometheus Biosciences TTM cash flow from operations?
The current TTM CFO of RXDX is -$133.41 M
What is the all time high TTM CFO for Prometheus Biosciences?
Prometheus Biosciences all-time high TTM cash flow from operations is -$5.26 M
What is Prometheus Biosciences TTM CFO year-on-year change?
Over the past year, RXDX TTM cash flow from operations has changed by -$59.51 M (-80.53%)